Prd2175434 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
113 | Muscular dystrophy | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2015-003195-68-GB (EUCTR) | 11/11/2015 | 26/10/2015 | Testosterone therapy in DMD | Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy. - Testosterone therapy in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sustanon 250 Product Name: Sustanon 250 Product Code: PRD2175434 INN or Proposed INN: testosterone propionate INN or Proposed INN: testosterone phenylpropionate INN or Proposed INN: testosterone isocaproate INN or Proposed INN: testosterone decanoate | The Newcastle upon Tyne NHS Hospitals Foundation Trust | NULL | Not Recruiting | Female: no Male: yes | 20 | Phase 3 | United Kingdom |